Audentes Therapeutics, Inc. (NASDAQ:BOLD) SVP Mary Newman sold 10,000 shares of the company’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. Following the completion of the transaction, the senior vice president now owns 10,000 shares of the company’s stock, valued at $200,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Audentes Therapeutics, Inc. (NASDAQ BOLD) opened at 21.34 on Friday. The firm’s market capitalization is $592.91 million. The company has a 50-day moving average price of $19.73 and a 200 day moving average price of $17.01. Audentes Therapeutics, Inc. has a 1-year low of $13.13 and a 1-year high of $22.82.

Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.10. Equities analysts anticipate that Audentes Therapeutics, Inc. will post ($3.53) earnings per share for the current year.

WARNING: This piece was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://theolympiareport.com/2017/08/27/mary-newman-sells-10000-shares-of-audentes-therapeutics-inc-bold-stock.html.

Several equities analysts recently commented on BOLD shares. Zacks Investment Research lowered Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. ValuEngine upgraded Audentes Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. Leerink Swann started coverage on Audentes Therapeutics in a research note on Monday, May 1st. They issued an “outperform” rating and a $22.00 target price for the company. Evercore ISI started coverage on Audentes Therapeutics in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 target price for the company. Finally, Wedbush reiterated an “ourperform” rating and issued a $20.00 target price on shares of Audentes Therapeutics in a research note on Monday, May 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $22.40.

A number of institutional investors have recently made changes to their positions in the company. TD Asset Management Inc. raised its position in shares of Audentes Therapeutics by 2.4% in the second quarter. TD Asset Management Inc. now owns 25,280 shares of the biotechnology company’s stock worth $484,000 after buying an additional 598 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Audentes Therapeutics by 27.1% in the second quarter. ProShare Advisors LLC now owns 15,581 shares of the biotechnology company’s stock worth $298,000 after buying an additional 3,324 shares during the last quarter. Bank of America Corp DE raised its position in shares of Audentes Therapeutics by 22.6% in the first quarter. Bank of America Corp DE now owns 23,399 shares of the biotechnology company’s stock worth $399,000 after buying an additional 4,310 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Audentes Therapeutics by 36.2% in the first quarter. Bank of New York Mellon Corp now owns 18,843 shares of the biotechnology company’s stock worth $321,000 after buying an additional 5,009 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of Audentes Therapeutics by 278.5% in the first quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock worth $132,000 after buying an additional 5,700 shares during the last quarter. 59.76% of the stock is owned by hedge funds and other institutional investors.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.